First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Short Interest Update

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the target of a significant decline in short interest in February. As of February 15th, there was short interest totalling 700 shares, a decline of 41.7% from the January 31st total of 1,200 shares. Based on an average daily volume of 2,800 shares, the short-interest ratio is currently 0.3 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vivaldi Capital Management LP lifted its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 15.6% in the fourth quarter. Vivaldi Capital Management LP now owns 8,677 shares of the company’s stock worth $243,000 after acquiring an additional 1,171 shares during the last quarter. Summit Investment Advisors Inc. grew its holdings in shares of First Trust Nasdaq Pharmaceuticals ETF by 13.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,173 shares of the company’s stock valued at $382,000 after purchasing an additional 1,633 shares during the last quarter. Envestnet Asset Management Inc. increased its position in First Trust Nasdaq Pharmaceuticals ETF by 17.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 16,403 shares of the company’s stock worth $442,000 after purchasing an additional 2,384 shares in the last quarter. Finally, LPL Financial LLC lifted its stake in First Trust Nasdaq Pharmaceuticals ETF by 9.3% in the 4th quarter. LPL Financial LLC now owns 55,876 shares of the company’s stock valued at $1,507,000 after purchasing an additional 4,776 shares during the last quarter.

First Trust Nasdaq Pharmaceuticals ETF Trading Down 0.2 %

NASDAQ FTXH traded down $0.05 on Tuesday, hitting $28.13. 1,143 shares of the company’s stock were exchanged, compared to its average volume of 3,169. The stock has a 50-day moving average of $27.43 and a 200-day moving average of $28.13. The stock has a market cap of $15.47 million, a price-to-earnings ratio of 20.07 and a beta of 0.63. First Trust Nasdaq Pharmaceuticals ETF has a 52 week low of $25.73 and a 52 week high of $29.72.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The firm also recently disclosed a dividend, which was paid on Tuesday, December 31st. Investors of record on Friday, December 13th were given a dividend of $0.1304 per share. This is an increase from First Trust Nasdaq Pharmaceuticals ETF’s previous dividend of $0.13. The ex-dividend date of this dividend was Friday, December 13th.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.